Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Wells

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Analytical Biochemistry|January 30, 2002
Supercritical fluid extraction and high-performance liquid chromatography-diode array-electrochemical detection of signature redox compounds from sand and soil samplesQingyong Lang, I Francis Cheng, Chien M Wai, et al.
Patient Preference and Adherence|April 21, 2020
Assessing Preferences for Rare Disease Treatment: Qualitative Development of the Paroxysmal Nocturnal Hemoglobinuria Patient Preference Questionnaire (PNH-PPQ<sup>©</sup>)Karen Kaiser, Susan E Yount, Christa E Martens, et al.
Leukemia & Lymphoma|January 30, 2010
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group StudyMichael Crump, David Hedley, Suzanne Kamel-Reid, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|May 10, 2005
Molecular characterization of salivary gland malignancy using the Smgb-Tag transgenic mouse modelAntti A Mäkitie, Patricia Pintor Dos Reis, Shilpi Arora, et al.
Stem Cells (Dayton, Ohio)|May 29, 2013
TNF, acting through inducibly expressed TNFR2, drives activation and cell cycle entry of c-Kit+ cardiac stem cells in ischemic heart diseaseRafia S Al-Lamki, Wanhua Lu, Jun Wang, et al.
Blood|April 15, 2020
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover studyGuillermo Garcia-Manero, Elizabeth A Griffiths, David P Steensma, et al.
European Journal of Haematology|December 10, 2020
One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumabAustin G Kulasekararaj, Anita Hill, Saskia Langemeijer, et al.
Blood|December 5, 2018
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 studyAustin G Kulasekararaj, Anita Hill, Scott T Rottinghaus, et al.
JACC. Cardiovascular Imaging|September 15, 2012
Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosisMaysoon Elkhawad, James H F Rudd, Lea Sarov-Blat, et al.
Plos One|September 4, 2020
Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuriaJohn Devin Peipert, Austin G Kulasekararaj, Anna Gaya, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Analytical Biochemistry|January 30, 2002
Supercritical fluid extraction and high-performance liquid chromatography-diode array-electrochemical detection of signature redox compounds from sand and soil samplesQingyong Lang, I Francis Cheng, Chien M Wai, et al.
Patient Preference and Adherence|April 21, 2020
Assessing Preferences for Rare Disease Treatment: Qualitative Development of the Paroxysmal Nocturnal Hemoglobinuria Patient Preference Questionnaire (PNH-PPQ<sup>©</sup>)Karen Kaiser, Susan E Yount, Christa E Martens, et al.
Leukemia & Lymphoma|January 30, 2010
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group StudyMichael Crump, David Hedley, Suzanne Kamel-Reid, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|May 10, 2005
Molecular characterization of salivary gland malignancy using the Smgb-Tag transgenic mouse modelAntti A Mäkitie, Patricia Pintor Dos Reis, Shilpi Arora, et al.
Stem Cells (Dayton, Ohio)|May 29, 2013
TNF, acting through inducibly expressed TNFR2, drives activation and cell cycle entry of c-Kit+ cardiac stem cells in ischemic heart diseaseRafia S Al-Lamki, Wanhua Lu, Jun Wang, et al.
Blood|April 15, 2020
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover studyGuillermo Garcia-Manero, Elizabeth A Griffiths, David P Steensma, et al.
European Journal of Haematology|December 10, 2020
One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumabAustin G Kulasekararaj, Anita Hill, Saskia Langemeijer, et al.
Blood|December 5, 2018
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 studyAustin G Kulasekararaj, Anita Hill, Scott T Rottinghaus, et al.
JACC. Cardiovascular Imaging|September 15, 2012
Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosisMaysoon Elkhawad, James H F Rudd, Lea Sarov-Blat, et al.
Plos One|September 4, 2020
Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuriaJohn Devin Peipert, Austin G Kulasekararaj, Anna Gaya, et al.
Pageof 6